Can IVF Be Done for Habitual Abortion in China? Full Analysis of Indications and Medical Conditions

AI Summary

When encountering patients with habitual abortion in the reproductive clinic, the doctor's first concern is not "Can IVF be done?" but "What exactly is the cause of the miscarriage?" This decision-making sequence directly determines the success rate of subsequent treatment. Habitual abortion is medically defined as two or more consecutive pregnancy failures (including biochemical pregnancies), affecting approximately 1%–5% of couples of reproductive age. For such patients, IVF technology is not a universal solution, but it is indeed an effective intervention in specific situations.

When is IVF Suitable and When is it Not

There are three main groups of people suitable for IVF: The first group includes couples or embryos with clear chromosomal abnormalities, including structural abnormalities such as balanced translocations, Robertsonian translocations, inversions, and an increased rate of embryonic aneuploidy due to advanced maternal age. The second group includes those with unexplained recurrent miscarriage, where no definite cause is found after systematic screening, and there have been multiple miscarriages with chromosomally normal embryos. The third group includes carriers of certain single-gene genetic disorders who need to use PGT-M technology to block genetic transmission.

Situations not suitable for direct IVF include: uncorrected uterine structural abnormalities (such as intrauterine adhesions, septate uterus, submucosal fibroids), uncontrolled autoimmune diseases (such as antiphospholipid syndrome without anticoagulant therapy), suboptimal thyroid function or diabetes, and untreated coagulation abnormalities. In these cases, treatment by the relevant department is required first, and the feasibility of IVF should be reassessed once conditions are met.

The Medical Logic of IVF for Habitual Abortion

IVF technology itself does not directly treat miscarriage but reduces the risk of miscarriage through two pathways: First, by performing preimplantation genetic testing (PGT) to screen out embryos with chromosomal abnormalities and only transfer chromosomally normal embryos. Second, by obtaining multiple eggs through controlled ovarian stimulation, increasing the probability of obtaining normal embryos. For carriers of chromosomal structural abnormalities, PGT-SR technology can screen for embryos that do not carry the abnormal chromosome, reducing the miscarriage rate from 80%–90% to below 10%.

It is important to clarify that IVF cannot solve miscarriages caused by maternal immune, coagulation, or endocrine issues. If a patient undergoes embryo transfer directly without correcting these factors, miscarriage can still occur even if the embryo is normal. Therefore, comprehensive etiological screening is a prerequisite for determining the IVF strategy.

Key Examination Items and Indicator Interpretation

Before considering IVF, patients with habitual abortion need to complete the following systematic etiological screening. Each examination has clear clinical significance and directly determines the subsequent treatment plan.

Among these, karyotype analysis and hysteroscopy are core items. Approximately 30%–40% of habitual abortions can find a clear cause through these two examinations. For older patients (≥35 years), the risk of embryonic aneuploidy increases exponentially with age, and the benefit of PGT-A is more evident.

Complete Process for Habitual Abortion Patients Undergoing IVF

From the initial consultation to embryo transfer, it generally takes 3–6 months, depending on the complexity of the etiological screening and the pretreatment plan.

1. Initial Consultation and History Taking: Record in detail the gestational week of each miscarriage, presence or absence of fetal heartbeat, whether miscarriage tissue testing was done, previous surgical history, family history, etc.
2. Comprehensive Etiological Screening: Complete the examination items in the table above; results are usually available within 4–6 weeks.
3. Multidisciplinary Consultation: The reproductive doctor collaborates with rheumatology, endocrinology, hematology, and genetic counselors to formulate a plan.
4. Pretreatment Therapy: For example, hysteroscopic surgery for uterine septum, low molecular weight heparin + aspirin for antiphospholipid syndrome, medication to adjust TSH to <2.5 mIU/L for thyroid dysfunction.
5. Entering the IVF Cycle: Choose an ovarian stimulation protocol based on ovarian reserve (AMH, FSH, antral follicle count); generally takes 8–14 days.
6. Egg Retrieval and Embryo Culture: Perform ICSI fertilization after egg retrieval, culture embryos to the blastocyst stage, biopsy trophectoderm cells for PGT.
7. Frozen Embryo Transfer: PGT results usually take 14–21 days; select chromosomally normal embryos for frozen-thawed transfer.
8. Luteal Phase Support After Transfer: Use progesterone preparations to maintain endometrial receptivity; pregnancy test 12–14 days after transfer.

Five Most Easily Overlooked Details

In clinical work, several details are often overlooked by patients but have a significant impact on the outcome.

• Genetic Testing of Miscarriage Tissue: Many patients do not undergo embryonic chromosome analysis after miscarriage, leaving doctors unable to determine whether the cause was an embryonic abnormality or a maternal factor. This is the most critical information gap.
• Male Sperm DNA Fragmentation Index (DFI): High DFI (≥30%) is clearly associated with recurrent miscarriage, but routine semen analysis cannot reflect this issue. A separate DFI test is required.
• Positive Thyroid Antibodies: Even if TSH is normal, positive thyroid peroxidase antibodies (TPO-Ab) increase the risk of miscarriage and require attention.
• Vitamin D Levels: Vitamin D deficiency is associated with immune disorders and an increased risk of miscarriage; it is recommended to check and supplement to normal levels.
• Luteal Phase Support Protocol: Luteal phase support for patients with habitual abortion needs to be more individualized, including dosage, route of administration (oral, vaginal, or injection), and duration; standard protocols should not be directly copied.

Four Most Common Misconceptions

Below are common misconceptions patients may fall into when making decisions, requiring special attention.

• Misconception 1: "IVF can solve the miscarriage problem." In reality, if the cause is immune or coagulation issues, IVF cannot solve it; treatment must come first. It is not uncommon for miscarriage to still occur after transferring a normal embryo.
• Misconception 2: "Directly doing third-generation IVF (PGT) means no need to check the cause." PGT only screens embryonic chromosomes, not maternal factors. Direct transfer without etiological screening can still result in a high miscarriage rate even with normal PGT.
• Misconception 3: "Miscarriage is always the woman's fault." About 30%–40% of recurrent miscarriages are related to male factors, including sperm chromosomal abnormalities, high DFI, Y chromosome microdeletions, etc. Male examination is equally important.
• Misconception 4: "A comprehensive check-up done once is valid forever." Some test results have an expiration date, such as AMH, sex hormones, and semen analysis. If more than 6–12 months have passed, re-examination is needed, especially as ovarian reserve may change with age.

Frequently Asked Questions from Patients

Q1: What is the success rate of IVF for habitual abortion?

The success rate depends on the specific cause and age. If the cause is embryonic chromosomal abnormalities, after screening for normal embryos via PGT, the live birth rate per single transfer can reach 50%–65% (under 35 years old). For unexplained cases after multiple cycles, the live birth rate is about 40%–55%. For those over 40, even with normal PGT, the live birth rate drops below 30%. An individual assessment by a doctor is necessary.

Q2: How many IVF cycles are needed for success?

There is no fixed number. Some patients succeed after one transfer, while others need multiple cycles. The key is to analyze the reasons after each failure and adjust the plan. If no normal embryos are obtained after two consecutive cycles, the ovarian stimulation protocol should be reassessed, or the possibility of egg/sperm donation should be considered.

Q3: How long should I prepare before IVF?

If no issues requiring treatment are found after screening, you can directly enter the cycle. If problems like uterine septum, intrauterine adhesions, or APS are found, surgical or medical treatment for 1–3 months is needed first. It is generally recommended to start taking folic acid and Coenzyme Q10 (for older women) 2–3 months in advance and adjust lifestyle habits.

Q4: What is the difference between domestic and overseas treatment?

Domestic reproductive centers have reached international standards in PGT technology, genetic counseling, and the diagnosis and treatment of immune-related miscarriages, with lower costs and easier communication. The advantages of overseas countries (such as the USA, Japan, Thailand) include more flexible egg/sperm donation policies in some countries and earlier detection technologies for certain special genetic diseases. For most patients with habitual abortion, qualified domestic reproductive centers can fully address the issue.

Q5: Can I still do IVF with low AMH?

Low AMH indicates reduced ovarian reserve, but as long as eggs can be obtained and embryos formed, there is a chance. People with low AMH need a more individualized ovarian stimulation protocol and may require multiple cycles to accumulate embryos. At the same time, low AMH is not directly related to an increased risk of miscarriage; it mainly affects the number of eggs retrieved rather than embryo quality.